biostudies-literatureUnknown43(1)Jirovec EUniversity of Helsinki<h4>Background</h4>A limitation of approved oncolytic viruses is their requirement for intratumoral (i.t.) injection. TILT-123 (igrelimogene litadenorepvec, Ad5/3-E2F-D24-hTNFα-IRES-hIL-2) is a chimeric oncolytic adenovirus suitable for intravenous (i.v.) delivery due to its capsid modification and dual selectivity devices. It is armed with tumor necrosis alpha and interleukin-2 for promoting T-cell activation and lymphocyte trafficking to tumors, thereby enhancing the antitumor immune response. Here, we present the findings after a single i.v. administration of TILT-123 in three phase I dose escalation clinical trials.<h4>Methods</h4>Patients with advanced solid tumors initially received a single i.v. dose of TILT-123 ranging from 3 × 10⁹ to 4 × 10¹² viral particles Journal of experimental & clinical cancer research : CR297https://www.ebi.ac.uk/biostudies/studies/S-EPMC11539705biostudies-literatureSingle intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors.PMC11539705Alanko TKhammari ACervera-Carrascon VBlock MSHaybout LDreno BAdamo DASvane IMKudling TQuixabeira DCAJalkanen KArias VPakola SAHemminki OKanerva AMaenpaa JKistler CSantos JMMonberg TSorsa SHemminki AJirovec EClubb JHAfalseSingle intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors.<h4>Background</h4>A limitation of approved oncolytic viruses is their requirement for intratumoral (i.t.) injection. TILT-123 (igrelimogene litadenorepvec, Ad5/3-E2F-D24-hTNFα-IRES-hIL-2) is a chimeric oncolytic adenovirus suitable for intravenous (i.v.) delivery due to its capsid modification and dual selectivity devices. It is armed with tumor necrosis alpha and interleukin-2 for promoting T-cell activation and lymphocyte trafficking to tumors, thereby enhancing the antitumor immune response. Here, we present the findings after a single i.v. administration of TILT-123 in three phase I dose escalation clinical trials.<h4>Methods</h4>Patients with advanced solid tumors initially received a single i.v. dose of TILT-123 ranging from 3 × 10⁹ to 4 × 10¹² viral particles 2024-01-01T00:00:00Z2024 Nov2026-06-01T15:21:51.338Z2025-04-06T10:12:02.175ZS-EPMC115397053950685610.1186/s13046-024-03219-0